Download - Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012
![Page 1: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/1.jpg)
Vesicant InfusionsA presentation for King Edward VII Memorial Hospital, Bermuda
23 January, 2012
Kristen Bodnaruk, RN, BSDenise Dreher, RN, CRNI, VA-BC
Mary McCormick-Gendzel, RN, MS, CRNI, RN-BC
![Page 2: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/2.jpg)
Today’s Discussion:
• Definitions• Patient safety• Peripheral and central VAD assessments• Equipment• Healthcare worker safety• Drug administration• Extravasation
![Page 3: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/3.jpg)
Definitions
• Irritant: medication that may cause itching, phlebitis, or reaction along the vessel or at the injection site.
• Vesicant: any IV drug that can cause blistering, severe tissue injury or tissue necrosis when extravasated. These may be chemotherapeutic or non-chemotherapeutic medications.
![Page 4: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/4.jpg)
Peripheral IV (PIV) Access• Gauge of catheter:
---bigger is not always better ---use smallest gauge possible to meet
infusion needs---smaller gauge decreases intimal damage and promotes hemodilution
• Placement of catheter: avoid areas of flexion such as the hand, wrist, or antecubital fossa
• Consider new PIV insertion daily if patient receiving daily vesicants• Start PIV insertions distally on arm and move proximally as therapy
regimen progresses
![Page 5: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/5.jpg)
Risk Factors• Patient age, condition, or acuity• Large gauge, location, and/or length of catheter• Infusion history• Poor VAD insertion technique• Poor care and maintenance practices• Extended dwell time• Chemical makeup of drug: pH <5 or >9, osmolarity
>600mOsm, or final dextrose concentration > 10%• Recent proximal peripheral venipunctures, or other
existing PIVs in the same extremity
![Page 6: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/6.jpg)
Risk Factors• Recent proximal peripheral venipunctures, or other
existing PIVs in the same extremity• Inadequate device securement• Confused or active patients could dislodge or damage
access• Improper length of non-coring needle used with port
access. • Inadequate device securement
![Page 7: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/7.jpg)
VAD Assessment• Patient comments/complaints• What is insertion date? (for PIVs)• Any swelling/edema noted…is transparent dressing
looking taut?...is ID bracelet tight?• Is skin blanched or cool to touch?• Positive blood return?• Any redness (erythema) or leaking at insertion site?• Any difficulty flushing?• Radiological confirmation of central line catheter tip
placement
![Page 8: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/8.jpg)
Some Potential Complications of Central Venous Access Devices (CVADs)
• Catheter occlusion• Vessel occlusion• Catheter rupture/fracture• Device rotation• Catheter migration• For implanted ports: improper insertion of
non-coring needle or needle dislodgement
![Page 9: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/9.jpg)
Equipment
• IV tubing containing DEHP: (di-2-ethylhexylphthalate) is a plasticizer added to PVC-based plastics to make them soft and pliable.
There is evidence that certain drugs cause more leaching of DEHP.
Increased amounts of DEHP in humans is concerning for its carcinogenic or hepatotoxic effects.
![Page 10: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/10.jpg)
Personal Protective Equipment (PPE)
• Long-sleeved protective gown or cover-up should be lint-free and made of a low-permeability fabric. Gown should have a solid front, back closure, and tight cuffs.
• Powder-free long-cuffed gloves designed specifically for chemotherapy should be worn. Gloves should be changed after each use, after 30 minutes of wear, or if they become torn or exposed to chemotherapy.
• Face shield, goggles, or safety glasses should be worn
![Page 11: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/11.jpg)
Healthcare Worker Safety
• Proper handling of infusates and administration sets• Caution with connecting and disconnecting• Proper use of PPE• Exercise caution when handling patient’s emesis,
urine, or feces• Disposal of equipment into the appropriate
biohazard bag or container• Follow established protocols and use a
chemotherapy spill kit when cleaning up spills
![Page 12: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/12.jpg)
Vesicant Administration
![Page 13: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/13.jpg)
General Points of Emphasis
• Continuous vesicants are given via central access.
• Pre-filled administration sets versus backpriming of tubings
• Vesicants are administered FIRST in a multiple chemo regimen
• Patient education!!
![Page 14: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/14.jpg)
Pre-infusion• Informed consent?• Patient education: including signs/symptoms to notify RN if
they feel any pain, burning, cool sensation, tingling, etc… at insertion site.
• Gather supplies:---clean pad or ‘chux’ to place supplies on at bedside---PPE---medication---alcohol wipes---empty 10ml syringe---bag of 0.9% saline (NS) with tubing
![Page 15: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/15.jpg)
Pre-infusion
• Check/double-check of correct medication and dosage per facility policies and procedures
• Review of patient’s height, weight, body surface area (BSA), and any pertinent lab values
• Patient identification using two verifiers
![Page 16: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/16.jpg)
Infusion
• Do you have “the three C’s?”…. correct patient, correct medication and dose, and correct VAD?
• Connect NS to VAD. Fluid should be fast and free-flowing. Chemotherapy should be connected at the lowest port closest to IV insertion site. Technique is known as “free-flowing side arm”.
![Page 17: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/17.jpg)
Infusion
• When giving an IVP medication, blood return must be assessed every 2-3ml of infusate given. It should be given in a slow, steady push.
• The NS should be free-flowing the entire time.• Site assessment should be on-going during
administration.• End with NS flush of 100-200ml.
![Page 18: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/18.jpg)
Peripheral IV Extravasation
![Page 19: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/19.jpg)
Port Extravasation
![Page 20: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/20.jpg)
Port Extravasation
![Page 21: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/21.jpg)
Extravasation
• Inadvertent administration of vesicant medication or solution into the surrounding tissue (INS, 2011)
![Page 22: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/22.jpg)
Extravasation• Any grade 4 infiltrate of a vesicant is considered an
extravasation• Incidence is similar for peripheral and central line
administration• Risk factors, such as fragile vessels, location of peripheral IV,
or catheter integrity are things to consider• Antidotes may be used, but are considered controversial in
some circles• Many non-chemotherapy agents have vesicant properties
(e.g., Dopamine, Epinephrine, Gentamycin, Mannitol)Reference: MGH NPROM 08-02-01
![Page 23: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/23.jpg)
Early warning signs of possible extravasation
• Swelling• Stinging, burning, or pain at insertion site• IV flow that stops or slows• Resistance when pushing medication• Leaking around the port needle• Lack of blood return• Erythema, inflammation, or blanching
![Page 24: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/24.jpg)
Other symptoms/damage resulting from extravasation
• Induration• Vesicle formation• Necrotic tissue damage can progress for six months• Tissue sloughing• Tendon, nerve, joint damage• Blistering at insertion site• Ulceration is usually seen 2-3 days to weeks
following extravasation
![Page 25: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/25.jpg)
Treatment of Extravasation• IMMEDIATELY STOP INFUSION• Remove tubing from VAD, attach syringe to VAD, and aspirate
drug• If via PIV, elevate extremity• Notify physician ASAP• Locate your institution’s policies or call Pharmacy for specific
antidote• Application of heat or cold• Documentation in patient’s medical record• Documentation via safety report
![Page 26: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/26.jpg)
DNA-binding agents
• Bind to the DNA in healthy cells when they extravasate into the tissue and cause cell death.
• Retained in the tissue for long periods of time and cause progressive tissue necrosis.
• Examples: anthracyclines (daunorubicin,doxorubicin, epirubicin, and idarubicin)
• Application of cold 15-20 minutes for four to six times daily for 24 to 48 hours
![Page 27: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/27.jpg)
Non-DNA binding agents
• Do not bind to the DNA in healthy cells, and are metabolized in the tissue
• Examples: plant alkaloids (vincristine, vinblastine, and vindesine)
• Application of heat 15 to 20 minutes for four to six times daily for 24 to 48 hours
![Page 28: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/28.jpg)
Some Available Antidotes
• Totect (dexrazoxane) for anthracycline extravasation
• Sodium thiosulfate for nitrogen mustard extravasation
• Hyaluronidase for vinca alkaloid extravasation
![Page 29: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/29.jpg)
Helpful Websites
• www.ins1.org• www.ons.org• www.cdc.gov/niosh
![Page 30: Vesicant Infusions A presentation for King Edward VII Memorial Hospital, Bermuda 23 January, 2012](https://reader035.vdocuments.mx/reader035/viewer/2022062520/5681644b550346895dd61287/html5/thumbnails/30.jpg)
References• Alexander, M., et al., Infusion Nursing. An Evidence-Based
Approach. INS, Saunders, 2010.• Policies and Procedures for Infusion Nursing. INS, fourth
edition, 2011.• Infusion Nursing Standards of Practice. INS, Lippincott, 2011.• Terry, et al. Intravenous Therapy: Clinical Principles and
Practice. INS. WB Saunders, 2001• Oncology Nurses Society (ONS) website• MGH Nursing Procedure Manual (NPROM)• MGH Clinical Policies and Procedures• MGH Infection Control Manual